Ongoing Clinical Trials

ONGOING CLINICAL TRIALS

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)- Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine
Principal Investigator: Dia R. Waguespack, MD
Study Coordinator: Iram Abbasi
Email: RenalResearch@uth.tmc.edu
Phone: 713-500-6820
Main Inclusion Criteria: Aged at least 18 years, with newly-diagnosed or relapsed AAV where treatment with Cyclophosphamide or rituximab is needed

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose in subjects with iron deficiency anemia and non-dialysis-dependent chronic kidney disease
Principal Investigator: Dia R. Waguespack, MD
Study Coordinator: Iram Abbasi
Email: RenalResearch@uth.tmc.edu
Phone: 713-500-6820
Main Inclusion Criteria: >18 years of age

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease
Principal Investigator: Dia R. Waguespack, MD
Study Coordinator: Iram Abbasi
Email: RenalResearch@uth.tmc.edu
Phone: 713-500-6820
Main Inclusion Criteria: >18 years of age

A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephritis
Principal Investigator: Dia R. Waguespack, MD
Study Coordinator: Iram Abbasi
Email: RenalResearch@uth.tmc.edu
Phone: 713-500-6820
Main Inclusion Criteria: 18 to 75 years of age

Pathway Exploration and Analysis in Renal Lupus (PEARL) – Phase 2
Principal Investigator: Dia R. Waguespack, MD
Study Coordinator: Iram Abbasi
Email: RenalResearch@uth.tmc.edu
Phone: 713-500-6820
Main Inclusion Criteria: >18 years of age